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Visual Abstract
Brain-derived neurotrophic factor (BDNF) secreted by neurons is a significant component of synaptic plasticity.
In humans, it is also present in blood platelets where it accumulates following its biosynthesis in megakaryocytes.
BDNF levels are thus readily detectable in human serum and it has been abundantly speculated that they may
somehow serve as an indicator of brain function. However, there is a great deal of uncertainty with regard to the
range of BDNF levels that can be considered normal, how stable these values are over time and even whether
Significance Statement
The presence of brain-derived neurotrophic factor (BDNF) in human blood has generated considerable
interest as illustrated by the very large number of publications associating BDNF levels with various
conditions affecting brain function, including depression and neurodegeneration. Yet a range of technical
issues, together with a lack of plausible mechanisms explaining this association, raise questions as to the
meaning and value of such measurements. This contribution deals with the feasibility of reliably measuring
BDNF levels in human serum and gives indications of the size of cohorts to be recruited for meaningful
differences to be observed between populations of interest.
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BDNF levels can be reliably measured in serum. Using monoclonal antibodies and a sandwich ELISA, this study
reports on BDNF levels in the serum of 259 volunteers with a mean value of 32.69  8.33 ng/ml (SD). The mean
value for the same cohort after 12 months was not significantly different (N  226, 32.97  8.36 ng/ml SD, p 
0.19). Power analysis of these values indicates that relatively large cohorts are necessary to identify significant
differences, requiring a group size of 60 to detect a 20% change. The levels determined by ELISA could be
validated by Western blot analyses using a BDNF monoclonal antibody. While no association was observed with
gender, a weak, positive correlation was found with age. The overall conclusions are that BDNF levels can be
reliably measured in human serum, that these levels are quite stable over one year, and that comparisons between
two populations may only be meaningful if cohorts of sufficient sizes are assembled.
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Introduction
Brain-derived neurotrophic factor (BDNF) is a member
of the neurotrophin family involved in many aspects of
neuronal function, as evidenced by a large number of
animal experiments as well as human genetics (Zagrebel-
sky and Korte, 2014). BDNF is not only found in the brain,
but also in circulating platelets in humans (Yamamoto and
Gurney, 1990) and megakaryocytes have recently been
reported to express the same transcripts as neurons
(Chacón-Fernández et al., 2016). As BDNF is released
from platelets during the process of blood coagulation, its
levels can be readily measured in serum. Even if it is still
entirely unclear why BDNF levels in platelets or serum
should reflect brain levels (see Discussion), these levels
have been associated with a number of conditions includ-
ing depression (Karege et al., 2002; Sen et al., 2008),
Huntington’s disease (Ciammola et al., 2007; Zuccato
et al., 2011), and Alzheimer’s disease (Laske et al., 2006).
However, whether or not BDNF levels can be reliably
determined in human serum is increasingly a matter of
debate (Zuccato et al., 2011). In addition, the very large
range of reported individual values raises questions as to
the plausibility of any disease conditions leading to sig-
nificant differences in the levels of BDNF in serum. Con-
cerns have also been expressed following reports that
different commercially available ELISA kits for measuring
BDNF in human serum give different values when the
same samples of human serum are tested (Polacchini
et al., 2015). There is then a pressing need to better
understand if it is indeed possible to reliably measure
BDNF concentrations in human serum before further con-
sidering the use of BDNF as a biomarker possibly reflect-
ing disease conditions or for monitoring therapies.
The goal of this study was to address this question with
an ELISA based on publically available monoclonal anti-
bodies, using a cohort of 259 healthy volunteers retested
after 12 months and to validate the ELISA results using
independent Western blot analyses.
Materials and Methods
Serum samples
Serum samples from a cohort of volunteers were col-
lected at the University Hospital of Basel (Switzerland) fol-
lowing a protocol approved by the local ethics committee
and in accordance with the terms of the Declaration of
Helsinki. All subjects (N 259, 178 females, 81 males) gave
written informed consent. All participants gave a first blood
sample (defined as Initial), with most participants (226)
agreeing to have a second sample drawn at a 12-month
follow-up visit (defined as 12-month). The age range was
between 18 and 70 years and the volunteers were of North-
ern Europe ethnicity. Blood was drawn from a cubital vein
into a S-Monovette 7.5 ml Z tube (with clotting activator;
Sarstedt), left to coagulate for 30 min at room temperature
(RT) and centrifuged at 2000 g at RT for 10 min. The serum
supernatant was stored at -80°C in 0.5 ml aliquots after
centrifugation within 1 h of blood sampling. Blood samples
for platelet counts and hematocrit values were collected at
the same time as blood samples used for the determination
of BDNF levels. Time of blood sampling was between 8 A.M.
and 12 P.M. in over 75% of the individuals examined.
ELISA
Antibodies
ELISA measurements were performed using a combi-
nation of BDNF monoclonal antibodies designated mAb
BDNF-#1 and mAb BDNF-#9 (Kolbeck et al., 1999). Both
are available at the Developmental Studies Hybridoma
Bank (DSHB), University of Iowa (http://dshb.biology.uio-
wa.edu). mAb-#1 was conjugated with biotin using sulfo-
NHS-LC-Biotin (ThermoFisher Scientific, catalog number
21435). MAb-#9 was conjugated with horseradish peroxi-
dase (HRP) using a peroxidase labeling kit (Roche,
11829696001) following manufacturer’s instructions or else
provided conjugated by Icosagen.
Protocol
Pierce NeutrAvidin-coated high-capacity plates (Ther-
moFisher Scientific; 15509) were incubated for two hours
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at RT with 200 l of 14 g/ml biotin-conjugated mAb-#1
diluted in phosphate buffer (0.1% Triton X-100 in 0.1 M
phosphate buffer: 0.1 M KH2PO4 and 0.1 M Na2HPO4; pH
7.6). Plates were then washed three times with blocking
buffer [1% bovine serum albumin (BSA); Sigma A2153 in
phosphate buffer], followed by the addition of 150 l
phosphate buffer. A total of 50 l of either standards or
diluted samples (both in blocking buffer) was then added
to the plate followed by incubation for 3 h at RT on a rotary
shaker. The standard was established using recombinant
BDNF (Regeneron/Amgen) diluted in blocking buffer. Se-
rum samples were tested at 1:20 dilution, but identical
final values were also obtained with 1:10 and 1:40 dilu-
tions. After 3 washes with phosphate buffer, 200 l 1.25
g/ml HRP-conjugated mAb-#9 diluted in blocking buffer
was added and incubated for 3 h on a rotary shaker. The
plate was then washed three times with phosphate buffer
before the addition of 100 l chemiluminescent substrate
following manufacturer’s instructions (Chemiluminescence
ELISA Substrate, Roche 11582950001), and the plate im-
mediately analyzed with a microplate reader (FLUOstar
OMEGA, BMG Labtech). Recovery experiments indicated
108.6% recovery of known amounts (30 ng/ml) of recombi-
nant BDNF added to serum samples tested at the typical
1:20 dilution.
Western blotting
One microliter human serum was applied onto a 4–12%
NuPage Bis-Tris gradient gel (Invitrogen), alongside stan-
dards consisting of three different quantities of recombi-
nant BDNF (Regeneron/Amgen), typically 15, 30, and 50
pg; 0.1% BSA was added to recombinant BDNF to ap-
proximate the composition of the serum samples and to
improve the signal consistency between blots. The high
level of serum albumin precluded the use of higher vol-
umes of serum and albumin could not be selectively
removed from the serum samples without also removing
significant (50%) amounts of serum BDNF. Proteins
were transferred to 0.2 m Protran nitrocellulose mem-
branes (wet or semi-dry transfer at 80 V for 1 h at 4°C or
17V for 1.5 h at RT, respectively) and subsequently
blocked for 1 h with a solution containing 3% BSA (Sigma
A7906), 3% GE Healthcare ECL Prime Blocking reagent
(GE Healthcare) in TBS-T (blocking solution). The mem-
brane was then incubated overnight with primary antibody
[1:2000 anti-BDNF (3C11, Icosagen)] in blocking solution.
Following three 20-min washes with TBS-T, the mem-
branes were incubated for 1 h with 1:2000 secondary
antibody (HRP-conjugated goat anti-mouse IgG1; Invitro-
gen) in blocking solution, washed once with TBS-T, three
times with Lumiglo Reserve wash solution (Insight Biotech-
nology) and developed using Lumiglo Reserve Chemilumi-
nescent Substrate. Signals were recorded on a ChemiDoc
MP Imaging System (Bio-Rad) and quantified using Image
Lab V5.0 (Bio-Rad) and BDNF readings only considered
when the r2 value of the standards was above 0.98, and
the serum samples readings within the range of the stan-
dards. The limit of reliable BDNF detection by Western
blotting was 15 ng/ml.
Statistical analysis
As BDNF measurements were not normally distributed
the values were log-transformed before analysis of signif-
icance. The association between initial BDNF values and
both age and gender was assessed using a multivariable
linear regression model. Hematocrit and platelet count
were included as co-variables. Initial and 12-month BDNF
measurements were modeled using generalised estimat-
ing equations to examine the association of BDNF to the
various predictors while taking into account the dependence
of data from the same volunteer. The p value between the
first and second measurements was determined using
paired t test.
Results
Given various reports on the heterogeneity of values
obtained using commercially available BDNF ELISA kits
(Polacchini et al., 2015), a slightly modified version of a
previously described ELISA protocol was used (Kolbeck
et al., 1999) based on publically available BDNF mono-
clonal antibodies (http://dshb.biology.uiowa.edu/). This
assay has an interassay coefficient of variability of 8.8%
as calculated with a single serum sample measured on 18
different plates [24.11  2.12 ng/ml (SD); range, 20.63–
28.66 ng/ml]. The intra-assay coefficient of variability was
calculated as 9.7% based on 253 samples tested in trip-
licate. This ELISA was used to determine the serum BDNF
levels in a cohort of volunteers (n  259) and to monitor
these levels in most of these volunteers (n  226) over a
12-month period. Cohort demographics are listed in Table 1.
Serum samples were collected following a strict protocol
(see Methods), as the procedures used to collect the
blood samples and to generate serum following blood
collection are expected and indeed known to cause vari-
ability given that the bulk of BDNF eventually measured in
serum is released from platelets (see Discussion). The
values determined in the serum of 259 healthy volunteers
are summarized in Table 2. The mean serum value (SD)
of BDNF at the first visit was 32.69  8.33 ng/ml; the
median value was 30.86 ng/ml. The mean serum value in
participants 12 months later was 32.97  8.36 ng/ml with
a median of 32.27 ng/ml (Fig. 1), i.e., statistically indistin-
Table 1. Cohort characteristics at Initial (n  259) and 12-
month visit (n  226)
Visit 1 Visit 2
N 259 226
Age in years [mean (SD)] 44.31 (11.26) 46.11 (10.80)
Sex [males (%)] 81 (31.3) 74 (32.7)
Time between samples in
months [mean (SD)]
12.87 (2.21)
Table 2. Summary statistics for BDNF values in serum sep-
arated by gender
Variable Gender N Mean (ng/ml) SD (ng/ml) p
BDNF V1 F 178 32.85 8.57
0.7
M 81 32.34 7.82
BDNF V2 F 152 32.98 8.47
0.99
M 74 32.95 8.19
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guishable from the mean levels determined from the initial
blood samples (p  0.19). When analyzed in detail, over
half of the individuals retested after 12 months (55%) had
BDNF serum values within 10% of their original reading
(connected by blue lines seen in Fig. 1) with 37 individuals
showing 20% changes. In Figure 1, they are connected
by either yellow (20–30% change) or red lines (30%
change). The range of BDNF serum values was 15.83–
79.77 ng/ml, with a small, positive correlation with age
indicating an increase in serum BDNF levels of 0.33% for
every year of age (Fig. 2; p  0.031). The values of BDNF
content per platelet also indicate a significant, positive
correlation with age when pooling the corresponding data
(N  475, p  0.03; Fig. 3A). Platelet counts also signifi-
cantly (p  0.001; Fig. 3B) correlated with BDNF values
with an increase of 14.5% seen with every 100  109
increase in platelets. As reported previously (Butkiewicz
et al., 2006), there was a significant difference in platelet
counts between genders (p  0.0273) with mean platelet
counts (geometric mean) of 274.62 109 per ml blood for
female and 255.62  109 for male volunteers. In addition,
there is a significant association between BDNF levels
and hematocrit (p  0.001; Fig. 4). Mean hematocrit
values (geometric mean) were 39.52% for female and
44.04% for male volunteers, reflecting the known gender
difference (p  0.001; Vahlquist, 1950). However, no sig-
nificant gender-dependent differences were observed
with regard to the BDNF values in serum.
These ELISA results can also be used to estimate the size
of the cohorts needed to generate statistically significant re-
sults. Assuming equal group sizes, a variability of the measure-
ments of 0.24 (as observed here) and a t test of log-normally
distributed data with a significance level of 0.05, group sizes
of 60 and 200 will be needed to measure group differences of
20% or 10%, respectively, with 80% power (Fig. 5).
To validate these ELISA results, a subset of the col-
lected serum samples representing the lower and upper
ranges was analyzed by Western blotting (10 samples in
total; Fig. 6).
Discussion
Using the publicly available monoclonal antibodies
mAb BDNF-#1 and mAb BDNF-#9 and avidin-coated
ELISA plates, mean levels of BDNF in serum were found
to be stable over a period of 12 months among the 226
retested volunteers. Within the cohort, single values
ranged from a low 15.83 ng/ml to a high 79.77 ng/ml
despite a rigorous serum collection protocol. The need to
examine large cohorts is further illustrated by the finding
that as many as 37 individuals, i.e., 16% of the retested
volunteers, had values that differed by 20% or more 12
months after the initial samples were collected. Impor-
tantly, the mean values reported here could be confirmed
by Western blot analysis using a recently developed
BDNF monoclonal antibody allowing the detection of
BDNF in serum samples without pretreatment. Attempts
to deplete samples of major serum proteins, including
antibody-mediated adsorption or protein precipitation
failed as they led to losses of BDNF of at least 50% when
serum levels were determined by ELISA before and after
protein depletion. While the mean BDNF serum values
reported here fall within the range of a small number of
other studies (Shimizu et al., 2003; Lommatzsch et al.,
2005; Ziegenhorn et al., 2007), the published average
values range from below 1 ng/ml (Onen Sertoz et al.,
2008) to over 60 ng/ml (Matrisciano et al., 2009). This
Figure 1. BDNF serum levels in a healthy cohort at Initial (n  259) and 12-month (n  226) visit. Measurements of the same subject
are connected by a colored line to indicate percentage change in BDNF values between visits. Samples are separated on the x-axis
by age in years.
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variability has been previously explained by issues related
to serum collection (Maffioletti et al., 2014; Tsuchimine
et al., 2014) and to commercially available antibodies,
including antibody precoated plates (Polacchini et al.,
2015). In megakaryocytes BDNF is co-stored in  gran-
ules with PF4 (Chacón-Fernández et al., 2016) and neither
in megakaryocytes nor in pro-platelets did we find any evi-
dence for a cytoplasmic storage of BDNF (Tamura et al.,
Figure 2. BDNF serum levels and age of participant. The red broken line indicates the estimated serum BDNF for a given age in an
average volunteer.
Figure 3. Correlation between BDNF values and platelet counts. A, BDNF values per platelet plotted against age. B, The red broken
line indicates the estimated BDNF for a given platelet count in an average volunteer.
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2011), and it seems that only a fraction of the BDNF content
is released during the process of degranulation (Serra-
Millas, 2016). This partial release may be a consequence
of the dense BDNF packaging in platelets, its association
with other components in  granules and/or a conse-
quence of its physico-chemical properties, including its
high isoelectric point and hydrophobicity (Barde et al.,
1982; Hofer and Barde, 1988). In addition, various com-
monly used drugs including those known to interfere with
the biosynthesis of prostaglandins or of adenosine
diphosphate are likely to interfere with the release of
BDNF from platelets given their established roles in plate-
let aggregation (Stoll et al., 2011).
A major reason for the large number of publications
reporting on BDNF levels in serum is the intriguing asso-
ciation with numerous conditions including depression
(Karege et al., 2002; Sen et al., 2008) and neurodegen-
erative disorders such as Alzheimer’s disease (Laske
et al., 2006; Lee et al., 2009; Forlenza et al., 2010), Par-
kinson’s disease (Scalzo et al., 2010; Costa et al., 2015;
Wang et al., 2016), and Huntington’s disease (Ciammola
et al., 2007; Zuccato et al., 2011). Conversely, BDNF
levels have also been reported to increase after acute
exercise (Rojas Vega et al., 2006; Dinoff et al., 2017).
While the reality of an association between the levels of
BDNF in serum and any conditions has been questioned
(Zuccato et al., 2011), the results of several meta-analyses
suggest that these associations may be real (Brunoni
et al., 2008; Molendijk et al., 2014; Szuhany et al., 2015).
Importantly, post-mortem analyses of BDNF brain content
do indicate correlations between brain levels of BDNF and
the rate of cognitive decline in diseases such as Alzhei-
mer’s or Parkinson’s (Howells et al., 2000; Buchman et al.,
2016) and in depression (Thompson Ray et al., 2011).
However, there is still no plausible mechanism satisfac-
torily explaining how BDNF levels in blood may reflect
levels in the brain. The hypothesis that platelets may
somehow accumulate BDNF following its diffusion from
the brain into the vascular compartment appears unlikely.
Beside the lack of BDNF transporter in platelets (Fujimura
et al., 2002), intravenous injections of radiolabeled BDNF
into rats failed to show any accumulation in the brain,
indicating the inability of BDNF to cross the blood-brain
barrier (Pardridge et al., 1994). Furthermore, while rats
and mice express similar levels of BDNF in the brain,
BDNF can be readily detected in platelets and serum of
rats, but not of mice. The more plausible source account-
ing for the presence of BDNF in platelets are the platelet-
generating cells, namely megakaryocytes: they contain
readily detectable levels of BDNF in rats and humans, but
Figure 4. Correlation between BDNF values and hematocrit. The red broken line indicates the estimated BDNF for a given hematocrit
in an average volunteer.
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not in mice (Chacón-Fernández et al., 2016). Given the
additional finding that neuron-specific BDNF transcripts
have been detected in megakaryocytes it is conceivable
that conditions affecting BDNF transcription both in neu-
rons and megakaryocytes may explain correlations be-
tween the levels of BDNF in serum and in brain. However,
such transcriptional changes are unlikely to explain BDNF
increases after acute physical exercise whereby in-
creased release of BDNF from platelets, for example, as a
result of their fragmentation or activation, may appear
more likely (Posthuma et al., 2015). In general, as is the
case for several other growth factors and cytokines con-
tained in platelets, the functional relevance of BDNF in
platelets is still unclear though it is intriguing to note that
the serum levels of BDNF in all primates tested are com-
parable to those found in humans (Mori et al., 2003).
Accumulation of BDNF in platelets may have conferred a
survival advantage in long-lived species, for example by
contributing to tissue repair like may be the case for other
platelet-derived growth factors and cytokines.
Figure 5. Cohort size estimation as a function of expected difference between two populations. Thick gray lines indicate a power of
80%; fine gray lines indicate a power of 90%. A, Cohort size required for a 20% difference in BDNF values. B, Cohort size required
for a 10% difference in BDNF values.
Figure 6. Comparison of mean ELISA values with Western blotting determinations of the same serum samples. A, Western blotting
used to quantify BDNF in two different serum samples (1 l each) against a standard curve generated from three different quantities
of recombinant BDNF with added BSA. B, Comparison between mean values obtained by Western blotting versus those obtained by
ELISA. Error bars show SD, derived from at least three separate blots (WB) or three replicate wells in the same plate (ELISA).
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Among the various parameters tested, platelet numbers
were found to be the variable most significantly correlated
with BDNF serum values, in line with the fact that platelets
are the major source of BDNF in serum. However, this
correlation was not as strong as may have been antici-
pated (Fig. 3). Furthermore, while a significant difference
in platelet counts was found between genders (p 0.0273) as
previously reported (Butkiewicz et al., 2006) no significant
differences in the levels of BDNF between genders could
be observed, presumably a consequence of the relatively
weak correlation between BDNF values and platelet
counts. Also, while platelet numbers are known to de-
crease with age a moderate increase in BDNF serum
levels was observed with age (p  0.03; Fig. 3). It thus
appears that factors others than platelet numbers also
contribute to BDNF levels in serum, including platelet
reactivity. For example, it has been previously noted that
the release of  granule components such as PF4 in-
creases with age, for reasons that remain unclear (Zahavi
et al., 1980).
In conclusion, the results demonstrate that BDNF levels
can be reliably measured in human serum samples using
publicly available monoclonal antibodies. However, meaningful
comparisons require the recruitment of adequately-sized co-
horts given individual variations.
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